Source: Web Search Publisher: Stallion laboratories Pvt. Ltd., C-1B, 305/2,3,4 & 5, GIDC, Kerala (Bavla) Dist: Ahmedabad-382220, Gujarat, India
Pharmacotherapeutic group: Proton Pump Inhibitor
ATC code: A02BC07
Dexrabeprazole sodium belongs to the class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonist properties, but suppress gastric acid secretion by the specific inhibition of the H+/K+- ATPase enzyme at the secretory surface of the gastric parietal cell. This enzyme system is regarded as the acid (proton) pump, and therefore Dexrabeprazole sodium is classified as a gastric proton-pump inhibitor blocking the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus. Animal studies indicate that after administration, dexrabeprazole sodium rapidly disappears from both the plasma and gastric mucosa.
DEXRABEPRAZOLE SODIUM TABLETS indicated for Gastro esophageal reflux disease, gastric and duodenal ulcers.
Oral bioavailability: about 52% and peak plasma concentrations are reached about 3.5 hr after oral admin.
Protein-binding: 97%.
Extensively metabolised in the liver by cytochrome P450 isoenzymes.
Metabolites are mainly excreted in the urine (90%).
None stated.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
